电子烟或雾化产品使用相关的肺损伤以及全面感染性检查的风险和益处。
E-cigarette, or vaping, product use associated lung injury and the risks and benefits of a thorough infectious work-up.
作者信息
Lilley Jessica, Kravitz Shena, Haynes Zachary, Church Tyler, McKay Sean, Mertz Andrew
机构信息
Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Transitional Year Internship, Walter Reed National Military Medical Center, Bethesda, MD, USA.
出版信息
Respir Med Case Rep. 2021 Jun 29;33:101465. doi: 10.1016/j.rmcr.2021.101465. eCollection 2021.
As of February 2020, over 2800 cases of lung injury associated with vapes have been reported in all 50 states (Cullen et al., 2019) [1]. This case is about a 29-year-old female with a five-year history of vaping tetrahydrocannabinol (THC) who presented with symptoms consistent with e-cigarette, or vaping, product-use associated lung injury (EVALI). This case report is unique because this patient clinically improved on a lower dose of corticosteroids compared to other reported cases of EVALI. Additionally, this case report highlights the importance and difficulty of excluding other disease processes prior to treating patients for EVALI, particularly during the coronavirus disease 2019 (COVID-19) global pandemic.
截至2020年2月，美国50个州已报告了2800多例与电子烟相关的肺损伤病例（卡伦等人，2019年）[1]。本病例是一名29岁女性，有吸食四氢大麻酚（THC）电子烟的五年病史，出现了与电子烟或雾化产品使用相关的肺损伤（EVALI）症状。本病例报告具有独特性，因为与其他报告的EVALI病例相比，该患者在较低剂量的皮质类固醇治疗下临床症状有所改善。此外，本病例报告强调了在治疗EVALI患者之前排除其他疾病过程的重要性和难度，尤其是在2019年冠状病毒病（COVID-19）全球大流行期间。
Zotero 插件